TrialLeukemia2016

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.

G Garcia-Manero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.